

Test Ref. FB-7004-96291-1

Lab Ref. H125_ORD

Patient Name

Physician Name

Patient ID

Gender

Date of Birth

Blood Sample Date


Test Date

Male

2026-06-11

2026-06-11

TEST SCORES




FIBROSIS

1.00

F4

severe fibrosis/cirrhosis




ACTIVITY

1.00

A4

severe activity



STEATOSIS

1.00

S3

marked steatosis (≥67%)

INTERPRETATION

S3-A4-F4

Your result for the SAF score is S3-A4-F4. This score indicates that you have marked steatosis (≥67%), severe activity and severe fibrosis/cirrhosis. Consult your physician for further evaluation.

BIOMARKER VALUES

Age: 65 years

Height: * 1.2 m

Weight: 120 kg

BMI: * 83.33

Biomarker	Result	Unit	Biomarker	Result	Unit
Alpha2 Macroglobulin	250	mg/dL	ALT	* 12000	IU/L
Haptoglobin	* 3.3	mg/dL	AST	* 13000	IU/L
Apolipoprotein A1	* 4.5	mg/dL	Fasting Glucose	* 27	mg/dL
Total Bilirubin	18	mg/dL	Total Cholesterol	* 28	mg/dL
GGT	290	IU/L	Triglycerides	40	mg/dL

* NOTE: The highlighted value is at the extremes of the acceptable range of biomarker values.

WHAT LIVERFAST™ IS

LIVERFAST™ is a noninvasive panel of tests combining patients' age, gender and body mass index with 10 biological blood markers correlated with liver conditions, to generate 3 different scores for estimating 3 lesions: fibrosis, activity and steatosis.

For each lesion, LIVERFAST™ evaluates a quantitative score (0.00 to 1.00) and its estimated grade or stage, similar to the liver biopsy classification. LIVERFAST™ graphs display the calculated score and the estimated grade or stage with a color code (from green that signifies normal or early condition to red, a severe condition).


LIVERFAST™ algorithm was built according to the latest MASLD histopathologic scoring system for categorizing liver lesions, the SAF score*, that has two main advantages: to cover the entire spectrum of lesions (from S0A0F0 to S3A4F4) and to provide an activity score not biased by steatosis.

Liver damage (due to fibrosis, activity, steatosis) mainly due to metabolic syndrome risk factors (overweight, diabetes, excessive cholesterol, high blood pressure, etc.) or excessive alcohol intake can be improved by intensive lifestyle intervention (healthier lifestyle and/or reducing alcohol intake) and/or by drug treatment.

*Bedossa P. and al. Hepatology 2012;56:1751-9


HOW TO READ LIVERFAST™ RESULTS

Fibrosis is the progressive scarring of the liver leading to cirrhosis caused by the excessive accumulation of extracellular matrix, including collagen. Fibrosis could be reversible, more easily at early stages than late, and is mainly due to reaction from steatohepatitis (MASH)




Score	Stage	Interpretation
≥ 0.00 to < 0.07	F0	No fibrosis
≥ 0.07 to < 0.21	F1	Mild fibrosis
≥ 0.21 to < 0.52	F2	Significant fibrosis
≥ 0.52 to < 0.75	F3	Advanced fibrosis
≥ 0.75 to ≤ 1.00	F4	Severe fibrosis/cirrhosis

Activity related to MASLD is the inflammation and ballooning (severe hepatic cell injury) that occurs in the liver tissue which leads to steatohepatitis (MASH). MASH activity can be reversed.



Score	Grade	Interpretation
≥ 0.00 to < 0.15	A0	No activity
≥ 0.15 to < 0.24	A1	Mild activity
≥ 0.24 to < 0.42	A2	Moderate activity
≥ 0.42 to < 0.70	A3	Marked activity
≥ 0.70 to ≤ 1.00	A4	Severe activity

Steatosis is the accumulation of excessive fat (triglycerides) inside hepatocytes (liver cells). Steatosis is a reversible condition even at later stages.



Score	Grade	Interpretation
≥ 0.00 to < 0.19	S0	No steatosis (<5%)
≥ 0.19 to < 0.42	S1	Mild steatosis (5-33%)
≥ 0.42 to < 0.53	S2	Moderate steatosis (34-66%)
≥ 0.53 to ≤ 1.00	S3	Marked steatosis (≥67%)

NOTE: For readability, all score values shown are rounded to two significant digits – in boundary cases, where rounding suggests ambiguity, the stage rating should be considered as authoritative as the basis for interpretation. Graphs shown above are using sample data and are not based on the current patient's results.

CONTACT US



615 Baronne Street,
Suite 100, New Orleans,
LA, 70113, USA

888-552-1603

321-256-6061

For clinical questions regarding the LIVERFAST report please contact the **Medical Affairs team at medicalaffairs@fibronostics.com**

For clinical questions regarding the biomarker values please contact the **Client Services team at service@fibronostics.com**